C4 Therapeutics, Inc. (CCCC)
D
Pipeline Grade
Financial Position (from SEC Filings)
$64.7M
Cash & Equivalents
$29.9M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$449M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-30 | Phase1 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07284758 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myelom... | PHASE2 | Recruiting | 100 |
| NCT07280013 | A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myelom... | PHASE1 | Recruiting | 60 |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | PHASE1 | Active Not Recruiting | 224 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-11 | 8-K | C4 Therapeutics, Inc. (CCCC) (CIK 0001662579) - EX-99.3 | EDGAR |